The addition of anti-PD-L1 ICI amplifies this effect by enhancing specific populations of antitumoral CD8+ cells that express Ki67, IFN-γ, and granzyme B. Compared to the use of RT or anti-PD-L1 alone, the combination of these therapies increases CD8+ T cell infiltration in non-irradiated tumours and reverses the systemic ICI resistance induced by LM [20]. This evidence concerns the gene CD8A and neoplasm.